The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CANTATA: Randomized, international, double-blind study of CB-839 plus cabozantinib versus cabozantinib plus placebo in patients with metastatic renal cell carcinoma.
 
Nizar M. Tannir
Honoraria - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Nektar; Novartis; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Nektar; Novartis; Oncorena; Ono Pharmaceutical; Pfizer
Research Funding - Bristol-Myers Squibb; Epizyme; Exelixis; Mirati Therapeutics; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Nektar; Novartis; Onco Pharmaceuticals; Oncorena; Pfizer
 
Neeraj Agarwal
Consulting or Advisory Role - Argos Therapeutics; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; EMD Serono; Exelixis; Foundation One Inc; Genentech/Roche; Lilly; Medivation/Astellas; Merck; Nektar; Novartis; Pfizer
Research Funding - Active Biotech (Inst); Amgen (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Medivation (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Nancy Ann Dawson
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Eisai; Exelixis; Genentech/Roche; Janssen Biotech; Merck; Pfizer; Sanofi
Consulting or Advisory Role - Janssen Scientific Affairs
Speakers' Bureau - Amgen; Astellas Pharma; AstraZeneca; Eisai; Exelixis; Genentech/Roche; Janssen Biotech; Merck; Pfizer; Sanofi
Research Funding - Acceleron Pharma (Inst); Bayer (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Pfizer (Inst); Roche/Genentech (Inst); Tokai Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Incyte; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); Novartis (Inst); Pfizer (Inst)
 
Carmel Maree Jacobs
Honoraria - Merck Sharp & Dohme
 
Toni K. Choueiri
Honoraria - Alexion Pharmaceuticals; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; Exelixis; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Harborside Press; Ipsen; Kidney Cancer Association; Lancet Oncology; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; PER; Pfizer; PlatformQ Health; Prometheus; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - Alexion Pharmaceuticals; alligent; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; Ipsen; Kidney Cancer Association; Lancet Oncology; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Cerulean Pharma (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Foundation Medicine (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
John Stewart Hrom
No Relationships to Disclose
 
Daniel M. Geynisman
Consulting or Advisory Role - AstraZeneca; Exelixis; Pfizer; Seattle Genetics/Astellas
Research Funding - Astellas Pharma (Inst); Calithera Biosciences (Inst); Genentech (Inst); Merck (Inst)
 
Nancy B. Davis
Research Funding - AstraZeneca (Inst); Roche (Inst)
 
Robert A. Figlin
Stock and Other Ownership Interests - 4Dx; Revelar
Consulting or Advisory Role - Accelera; Bristol-Myers Squibb; CBT Pharmaceuticals; Johnson & Johnson; Precision Health Economics
Research Funding - Argos Therapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Merck (Inst); Peloton Therapeutics (Inst)
 
Mary Kathleen O'Keeffe
No Relationships to Disclose
 
Jigarkumar R. Parikh
No Relationships to Disclose
 
Daniel A. Vaena
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Exelixis; Genomic Health
Research Funding - Aeglea Biotherapeutics (Inst); AstraZeneca (Inst); BioClin Therapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Compugen (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Peloton Therapeutics (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst)
Travel, Accommodations, Expenses - Caris Centers of Excellence
 
Ping-Yu Liu
Consulting or Advisory Role - Calithera Biosciences; Carmenta Bioscience; Sarepta Therapeutics
 
Bridget O'Keeffe
Employment - Calithera Biosciences
Stock and Other Ownership Interests - Calithera Biosciences
 
Xuan Tran
Employment - Calithera Biosciences
Stock and Other Ownership Interests - Calithera Biosciences
 
Bernard Escudier
Honoraria - Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer